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A B S T R A C T
The aim of the present study was to investigate the relationship between homocysteine and homo-
cysteine metabolism components and retinal microvascular disorders in subjects with and without
Type 2 diabetes. In this population-based study of 256 participants, aged 60–85 years, we
determined total plasma homocysteine, SAM (S-adenosylmethionine) and SAH (S-adenosyl-
homocysteine) in plasma and erythrocytes, total folate in serum and erythrocytes, 5-MTHF
(5-methyltetrahydrofolate), and vitamins B12 and B6. Participants were examined ophthalmol-
ogically by means of indirect funduscopy and two-field 45◦ fundus photography, and were graded
for retinopathy and retinal sclerotic vessel abnormalities. A computer-assisted method was used
to measure retinal vessel diameters. Total plasma homocysteine was inversely associated with
retinal arteriolar diameters {standardized β , −0.20 [95% CI (confidence interval), −0.33 to
−0.07]} or a decrease of 3.78 μm CRAEs (central retinal arteriolar equivalents) per 1 S.D.
increase in homocysteine level (=4.6 μmol/l). In addition, the SAM/SAH ratio in plasma was
inversely associated with retinal sclerotic vessel abnormalities and retinopathy [odds ratios, 0.61
(95% CI, 0.39–0.96) and 0.50 (95% CI, 0.30–0.83) per 1 S.D. respectively]. The associations were
independent of age, sex, glucose tolerance status, other homocysteine metabolism components
and cardiovascular risk factors. In conclusion, the results of the present study support the concept
that total plasma homocysteine and a low SAM/SAH ratio in plasma, which may reflect reduced
transmethylation reactions, may contribute to the pathogenesis of (retinal) microangiopathy.
Key words: S-adenosylmethionine, S-adenosylhomocysteine, homocysteine, methionine metabolism, retinal microvascular disease,
retinopathy.
Abbreviations: AVR, arteriole-to-venule ratio; BMI, body mass index; CI, confidence interval; CRAE, central retinal arteriolar
equivalent; CRVE, central retinal venular equivalent; CV, coefficient of variation; CVD, cardiovascular disease; DBP, diastolic
blood pressure; HbA1c, glycated haemoglobin; HDL-cholesterol, high-density lipoprotein cholesterol; IGM, impaired glu-
cosemetabolism; LDL-cholesterol, low-density lipoprotein cholesterol; 5-MTHF, 5-methyltetrahydrofolate; NGM, normal glucose
metabolism; OGTT, oral glucose tolerance test; OR, odds ratio; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SBP,
systolic blood pressure.
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Figure 1 Methionine/homocysteine metabolism
B6, vitamin B6; B12, vitamin B12.
INTRODUCTION
Hyperhomocysteinaemia has been associated with an
increased risk of cardiovascular disease independently
of conventional cardiovascular risk factors [1,2]. It
remains unclear, however, whether homocysteine itself
is a direct cause of atherosclerosis. Other components
of homocysteine metabolism, such as SAM (S-adenosyl-
methionine), SAH (S-adenosylhomocysteine) and folate,
have also been suggested to play a role in, and possibly
mediate, the relationship with cardiovascular disease
[3–6]. Methionine/homocysteine metabolism involves
methionine transmethylation, which involves the form-
ation of SAM and SAH, and leads to the production of
homocysteine (Figure 1).Homocysteine canbe remethyl-
ated to methionine, which requires vitamin B12 and
folate, or can go through the trans-sulfuration pathway,
which requires vitamin B6. However, the exact extent
of contribution of these metabolites to cardiovascular
disease risk has not yet been established [7].
Homocysteine is thought to increase cardiovascular
risk by inducing endothelial dysfunction, increasing
oxidative stress, and inducing thrombophilia andprolifer-
ation of smoothmuscle cells, which can lead to narrowing
of the intravascular lumen [2,7–9]. Experimental studies,
mainly in rats, suggest that hyperhomocysteinaemia may
also play a role in the pathogenesis of renal microvascular
disease [10–12]. In humans, however, little is known
about the relationship between homocysteine and
its metabolites and microangiopathy. High levels of
homocysteine were reported to be strongly associated
with the development of microalbuminuria [13,14].
Hyperhomocysteinaemia is also thought to be a strong
risk factor for retinal vascular occlusive disease [15]. For
retinopathy, this relationship is not very clear. In the
Hoorn study, we have reported previously a relationship
between hyperhomocysteinaemia and retinopathy in
individuals with Type 2 diabetes [16], whereas others did
not find any relationship [17].
In light of these considerations, we hypothesized that
homocysteine and (or) components of homocysteine
metabolism are involved in the pathogenesis of microvas-
cular disease. As the retina offers a unique opportunity
to non-invasively analyse the microvasculature, we
investigated the relationship between homocysteine and
components of homocysteine metabolism and computer-
assisted measurements of retinal vessel diameters, retinal
sclerotic vessel abnormalities and retinopathy. Because
hyperhomocysteinaemia appears to be more strongly
related to cardiovascular disease in the presence of Type 2
diabetes [18], we studied the relationships mentioned
above in a population-based study of subjects with and
without Type 2 diabetes.
MATERIALS AND METHODS
Study population
For the present study, we used data from the 2000–2001
Hoorn Study follow-up examination. The Hoorn Study
is a population-based cohort study of Type 2 diabetes and
its cardiovascular complications among 2484 Caucasian
subjects, aged 50–74 years, which started in 1989. Full
details have been provided elsewhere [19,20]. Fasting and
2-h post-load plasma glucose levels after a 75-g OGTT
(oral glucose tolerance test) were measured in plasma,
and were used for classification into glucose tolerance
categories [21]. Subjects who were already known to
have diabetes or were using glucose-lowering treatment
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were excluded from the OGTT. At baseline, an age-, sex-
and glucose-tolerance-stratified subsample of 631 parti-
cipants was studied extensively for reasons of efficiency.
In 2000–2001, a follow-up examination was carried out
among surviving participants who gave their permission
to be re-contacted [20]. Of the 631 participants who
had an ophthalmological examination at baseline, approx.
60% dropped out of the follow-up examination because
of the following reasons: 119 (19%) had died, 49 (8%)
had moved out of the region and 207 (33%) did not par-
ticipate because of mobility or health problems, or lack
of motivation. Finally, 256 subjects were included in the
follow-up ophthalmological examination [22], 70 with
NGM (normal glucose metabolism), 69 with IGM (im-
paired glucose metabolism) and 109 with Type 2 diabetes
[21].
Written informed consent was obtained from all
participants. The Ethical Review Committee of the VU
University Medical Center (VUmc), Amsterdam, The
Netherlands, approved the Hoorn Study.
Sample preparation and determination
of homocysteine, SAM, SAH, folates
and vitamins
All samples were processed within 30 min after collec-
tion, stored at − 80 ◦C and analysed within 2 years.
EDTA-anticoagulated blood samples were put on ice for
the determination of homocysteine, SAM and SAH.
For SAM and SAH measurements, samples were depro-
teinized immediately by the addition of 0.625 ml of a
10% perchloric acid solution to 1 ml of plasma and by
adding 1 ml of 5% perchloric acid to 1 ml of whole
blood, followed by mixing [23]. For the determination of
total folate, 0.5 mg of ascorbic acid was added to 0.5 ml
of serum [23] and, for the determination of total folate in
erythrocytes, 1 ml of reagent with ascorbic acid, human
serum albumin and sodium azide (Chiron Diagnostics)
was added to 50 μl of whole blood.
Total plasma homocysteine was determined with an
automated fluorescence polarization immunoassay on an
Abbott Imx analyser {interassay CV (coefficient of vari-
ation) was 4%, where CV= S.D. of the mean difference/
[(square root of 2)×pooledmean]} [24]. TandemMSwas
used to determine SAM and SAH in plasma and whole
blood (intra-assayCVswere 4%forbothdeterminations,
and inter-assay CVs were 8% and 6% respectively)
[25]. Erythrocyte concentrations of SAM and SAH were
calculated as: [(whole blood concentration−plasma con-
centration)× (1−haematocrit)]/haematocrit. Total fol-
ate in serum and erythrocytes and serum vitamin B12
were measured with automated chemiluminescence
(180® Automated Chemiluminescence Systems; Chiron
Diagnostics). Intra- and inter-assays CV were 4% and
5% for total folate respectively. 5-MTHF (5-methyl-
tetrahydrofolate), the active form of folate, was measured
by HPLC [26], which was also used to measure plasma
vitamin B6 [27]. The inter-assay CV was 7%.
Ophthalmological examination and retinal
vessel diameter measurements
After mydriasis with 0.5% tropicamide and 2.5%
phenylephrine eye drops, the retina was examined by
funduscopy and fundus photography, as described previ-
ously [22]. Briefly, fundus photography was performed
with a 45 ◦CR5 non-mydriatic retinal camera (Canon),
interfaced to a 3CCD colour video camera (Sony). The
quality of each photographwas checked immediately on a
colour video monitor (Trinitron; Sony) and a new photo-
graph was taken if the quality was insufficient. The
photographs were digitized, compressed and stored on a
magneto-optical disc using the TEACMV-300P Viewfile
system. Two photographs were made of each eye, one
centred on the macula and one centred on the optic
disc.
Methods used to measure retinal vessel diameters
from digitized photographs followed a standardized
protocol, which has been described elsewhere [28].
Briefly, one investigator, blinded to the participant
identity, independently measured all arterioles and
venules 0.5 to 1 disc diameter from the optic disc margin
using a computer-imaging program (Retinal Analysis;
Optimate). The branches of arterioles were alsomeasured
if the trunk measures were 85 μm. Computer-assisted
measurements of the diameters of arterioles and venules
were obtained and combined according to the revised
formulas of Parr and Spears [29,30] and Hubbard et al.
[28,31], which account for magnification differences
and the number of vessels in photographs. Average
diameters of arterioles [CRAEs (central retinal arteriolar
equivalents)] and venules [CRVEs (central retinal venular
equivalents)] in one eye were assessed, and combined
into an AVR (arteriole-to-venule ratio). An AVR of
1.0 indicates that the diameters of the arterioles are
approximately equal to the diameters of the venules,
whereas a smaller AVR indicates narrower arterioles
or wider venules. For each subject, one photograph
centred on the optic disc was used, alternately selected
from the left and right eye (ratio, 50:50). In the case of
insufficient quality, the photograph of the other eye was
examined. The intra-observer intersession CVs were 5%
for CRVEs, 8% for CRAEs and 9% for AVRs.
Both fundus photographs were independently ana-
lysed by two individuals to grade retinal sclerotic
vessel abnormalities and retinopathy. In the case of
disagreement, the judgment of a third investigator was
taken to be decisive. Retinal sclerotic vessel abnormalities
were defined as the presence of venous beading, focal
narrowing, arteriovenous crossing changes, ‘copper’
or ‘silver’ wiring, dilated or tortuous retinal veins, or
central or branch venular occlusion. Retinopathy was
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defined as the presence of one or more microaneurysms,
haemorrhages or hard exudates, possibly in combination
with areas of neovascularization, fibrous proliferation,
pre-retinal or vitreous haemorrhages and/or laser
coagulation scars in at least one eye according to the
Eurodiab classification [22,32].
Other measurements
Brachial SBP (systolic blood pressure) andDBP (diastolic
blood pressure), HbA1c (glycated haemoglobin), fasting
insulin, serum total, HDL-cholesterol (high-den-
sity cholesterol), LDL-cholesterol (low-density lipopro-
tein cholesterol), serum triacylglycerols (triglycerides),
serum creatinine, serum albumin, BMI (body mass
index), waist and hip circumferences, smoking and prior
CVD (cardiovascular disease) were determined according
to methods described elsewhere [33–35]. Hypertension
was defined as a DBP 90 mmHg, a SBP 140 mmHg
and/or the use of antihypertensive medication [36].
Statistical analyses
Clinical and ophthalmological characteristics, expressed
as means+− S.D., percentages or medians (interquartile
range), in the case of a skewed distribution, were com-
puted according to tertiles of total plasma homocysteine
levels. Overall group differences in continuous variables
were tested by means of ANOVA, and the differences in
categorical measures were tested with Pearson’s χ 2 test.
Multivariable linear regression analyses were used to
calculate the associations between homocysteine and its
metabolites and AVRs, CRAEs and CRVEs. To make the
results of linear regressionmodels comparable among dif-
ferent determinants, standardized β values are reported.
A standardized β value of 0.1 indicates that, if the determ-
inant increases by 1 S.D., the outcome increases by 0.1
S.D. Furthermore, changes in AVRs, CRAEs and CRVEs
are reported. Logistic regression analyses were used to
calculate the associations of components of homocysteine
metabolismwith retinal sclerotic vessel abnormalities and
retinopathy [ORs (odds ratios) are reported per 1 S.D.].
Because all of the determinants had linearity with AVRs,
CRAEs,CRVEs, retinal sclerotic vessel abnormalities and
retinopathy, homocysteine and its metabolism compon-
ents were used as continuous variables in the models.
First, we adjusted the associations for the stratification
variables age, sex and glucose tolerance status. Then, we
additionally adjusted the associations of the other com-
ponents of homocysteine metabolism and for other
potential confounders, i.e. HbA1c, SBP, DBP, BMI, total
cholesterol, microalbuminuria, and prior CVD.
Effect-modification by Type 2 diabetes was investig-
ated by entering product terms of diabetes (yes/no)× the
predictor variable in the regression models. P values
<0.05 were considered statistically significant. All
analyses were performed in SPSS 12.0 for Windows 98.
RESULTS
Of the 256 participants, six had photographs that could
not be graded for AVRs and CRAEs, and two had photo-
graphs that could not be graded forCRVEs. Furthermore,
four subjects had data missing for total plasma homo-
cysteine, and 68 subjects had datamissing for one ormore
components of the homocysteine metabolism. Subjects
with one ormoremissing variables did not differ substan-
tially fromsubjectswith available data (results not shown)
and, therefore, were not excluded from further analyses.
The CRAE was 170.6+− 18.9 μm (range, 119.9–
225.1 μm), CRVE was 231.2+− 27.1 μm (range, 148.7–
333.5 μm) and AVR was 0.75+− 0.10 μm (range,
0.49–1.31 μm). Of the 256 subjects, 31 had retinal
sclerotic vessel abnormalities and 32 had retinopathy.
Clinical characteristics
Table 1 shows the clinical and ophthalmological
characteristics according to the tertiles of total plasma
homocysteine levels. AVRs and CRAEs were inversely
correlated with levels of homocysteine.
Associations between homocysteine, SAM
and SAH and retinal vessel diameter
Figure 2(a) shows the distribution of homocysteine
levels against CRAEs for subjects with NGM, IGM and
diabetes. Figure 2(b) shows that, after adjustment for age,
sex and glucose tolerance status, subjects in the highest
tertile of homocysteine had CRAEs 8 μm lower than
subjects with homocysteine levels in the lowest tertile
(P< 0.05). Indeed, when homocysteine was analysed as
a continuous variable, total plasma homocysteine was
inversely associated with CRAEs and AVRs after adjust-
ment for age, sex and glucose tolerance status (Table 2).
This implies that the CRAE decrease of 3.78 μm per
1 S.D. increase in homocysteine level (=4.6 μmol/l)
(Table 2). After additional adjustments for plasma SAM,
5-MTHF and cardiovascular risk factors, the association
of total plasma homocysteine with small retinal arteriolar
diameter did not change (Table 3). Furthermore, indi-
vidual adjustment for other components of homocysteine
metabolism and other cardiovascular risk factors, such as
lipid levels or current smoking, also did not affect the
results (results not shown).
High plasma SAM and SAH were both associated
with lower AVRs after adjustment for age, sex and
glucose tolerance status (Table 2). After adjustment for
5-MTHF, plasma homocysteine, plasma SAM, plasma
SAH, BMI, waist-to-hip ratio, waist circumference
or microalbuminuria, the associations lost statistical
significance. After adjustment for total folate in serum
and erythrocytes, or vitamins B6 and B12, the association
between SAM and SAH in plasma and lower AVRs
remained statistical significant (results not shown).
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Table 1 Baseline characteristics according to the tertiles of homocysteine levels
Values are means+− S.D. or percentages, or medians (interquartile range) in the case of skewed distribution. P values were calculated by ANOVA or a χ2 test.
Homocysteine tertile
< 10.0 μmol/l 10.0–12.7 μmol/l  12.8 μmol/l P value trend
n 85 83 84
Age (years) 69+− 6 72+− 7 74+− 7 < 0.001
Gender (% male) 47 49 61 0.076
HbA1c (%) 6.3+− 1.0 6.3+− 0.9 6.2+− 0.9 0.262
Diabetes (%) 41 46 42 0.894
Hypertension (%) 75 77 82 0.351
SBP (mmHg) 144+− 19 150+− 21 148+− 23 0.181
DBP (mmHg) 85+− 11 85+− 12 83+− 12 0.344
Use of ACE-inhibitor/calcium antagonist (%) 18.8 21.7 21.4 0.730
BMI (kg/m2) 27.2+− 4.0 27.2+− 3.6 27.8+− 4.5 0.345
Waist-to-hip ratio 0.94+− 0.10 0.94+− 0.09 0.95+− 0.09 0.306
Waist circumference (cm) 95.6+− 12.7 95.5+− 11.4 97.9+− 10.4 0.200
Total cholesterol (mmol/l) 5.7+− 1.1 5.9+− 1.0 5.6+− 1.0 0.623
HDL-cholesterol (mmol/l) 1.3+− 0.4 1.5+− 0.4 1.3+− 0.4 0.862
LDL-cholesterol (mmol/l) 3.5+− 0.9 3.7+− 0.9 3.6+− 0.8 0.861
Triacylglycerols (mmol/l) 1.5 (1.0–2.0) 1.4 (1.0–1.8) 1.4 (1.1–1.7) 0.186
Statin therapy (%) 17.6 12.0 10.7 0.375
Microalbuminuria (%) 14 19 21 0.234
Albumin-to-creatinine ratio 0.7 (0.5–1.3) 0.7 (0.5–1.6) 0.8 (0.5–1.9) 0.037
Current smoking (%) 11 10 16 0.329
Prior CVD (%) 45 59 57 0.261
AVR 0.76+− 0.12 0.75+− 0.09 0.72+− 0.10 0.024
CRAE (μm) 173+− 19 172+− 18 166+− 19 0.011
CRVE (μm) 231+− 30 232+− 27 231+− 25 0.900
Retinal vessel sclerosis (%) 9 18 17 0.184
Retinopathy (%) 9 16 13 0.458
Associations between SAM and SAH and
retinal sclerotic vessel abnormalities
and retinopathy
The SAM/SAH ratio in plasma was lower in subjects
with retinal sclerotic vessel abnormalities than in sub-
jects without retinal sclerotic vessel abnormalities [5.6
(4.5–6.5) compared with 6.0 (5.1–7.0) respectively;
P= 0.05]. In addition, plasma SAH was significantly
higher and the plasma SAM/SAH ratio was significantly
lower in subjects with retinopathy compared with
subjects without retinopathy [plasma SAH, 17.6 (15.6–
25.6) compared with 15.3 (12.5–20.2) nmol/l respectively
(P= 0.003); plasma SAM/SAH ratio, 5.1 (4.2–5.8)
compared with 6.0 (5.1–7.0) respectively (P< 0.001)].
After adjustment for age, sex and glucose tolerance
status, the plasma SAM/SAH ratio was inversely
and strongly associated with retinal sclerotic vessel
abnormalities and retinopathy (Table 2). Adjustments
for other homocysteine metabolism components had
little impact on either association. Further adjustments
for cardiovascular risk factors did not change the results
substantially, except for prior CVD, which slightly
attenuated the association of retinal sclerotic vessel
abnormalities (results not shown).
In addition, the plasma SAM/SAH ratio had a
borderline association with microalbuminuria after
adjustment for age, sex and glucose tolerance status
{microalbuminuria (yes/no) OR, 0.81 [95% CI (con-
fidence interval), 0.62–1.06]}. The standardized β value
for microalbuminuria as a linear variable was −0.153
(P= 0.029; S.D.= 28.1) (results not shown).
Additional analyses
The presence of Type 2 diabetes did not statistically
significantly (P> 0.05) modify the associations between
homocysteine metabolism components and AVRs,
CRAEs, CRVEs, retinal sclerotic vessel abnormalities or
retinopathy. Erythrocyte SAMand SAH, the erythrocyte
SAM/SAH ratio, 5-MTHF, total folate in serum and
in erythrocytes, and vitamins B12 and B6 were not
associated with AVRs, CRAEs, CRVEs, retinal sclerotic
vessel abnormalities and retinopathy (results not shown).
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Table 2 Age-, sex- and glucose-tolerance-status-adjusted associations between homocysteine, components of homocysteine metabolism and retinal vascular abnormalities
Values are calculated with linear regression analyses (for AVR, CRAE and CRVE) or with logistic regression analyses (for RSVC and retinopathy) and are shown as standardized β values (St. β ) (95 % CI)/change in AVR or μm CRAE/CRVE and ORs per
1 S.D. (95 % CI). RSVC, retinal sclerotic vessel abnormalities.
AVR [St.β (95 % CI)/change in ratio] CRAE [St.β (95 % CI)/change in μm] CRVE [St.β (95 % CI)/change in μm] RSVC [OR (95 % CI)] Retinopathy [OR (95 % CI)]
S.D. 0.1 18.9 μm 27.1 μm
Homocysteine 4.6 μmol/l − 0.15 (− 0.28 to − 0.01)/− 0.02 − 0.20 (− 0.33 to − 0.07)/− 3.78 − 0.04 (− 0.17 to 0.09)/− 1.03 0.97 (0.65–1.45) 0.98 (0.65–1.47)
SAM-plasma 28.5 nmol/l − 0.13 (− 0.26 to 0.00)/− 0.01 − 0.05 (− 0.18 to 0.07)/− 0.95 0.10 (− 0.02 to 0.23)/2.71 0.92 (0.62–1.36) 0.94 (0.64–1.40)
SAH-plasma 9.2 nmol/l − 0.15 (− 0.29 to − 0.01)/− 0.02 − 0.12 (− 0.25 to 0.01)/− 2.27 0.06 (− 0.07 to 0.19)/1.63 1.17 (0.85–1.62) 1.16 (0.84–1.60)
Plasma SAM/SAH ratio 1.5 0.05 (− 0.10 to 0.20)/0.01 0.09 (− 0.05 to 0.23)/1.70 0.02 (− 0.12 to 0.16)/0.54 0.61 (0.39–0.96) 0.50 (0.30–0.83)
5-MTHF 8.9 nmol/l 0.02 (− 0.13 to 0.16)/0.00 − 0.00 (− 0.14 to 0.13)/− 0.07 0.00 (− 0.14 to 0.14)/− 0.11 0.98 (0.67–1.44) 0.92 (0.59–1.45)
Vitamin B12 101.1 pmol/l − 0.01 (− 0.14 to 0.13)/−0.00 − 0.03 (− 0.16 to 0.09)/− 0.57 − 0.02 (− 0.15 to 0.12)/− 0.54 1.11 (0.74–1.64) 1.01 (0.68–1.49)
Vitamin B6 37.2 nmol/l 0.03 (− 0.10 to 0.16)/0.00 − 0.06 (− 0.18 to 0.06)/− 1.13 − 0.10 (− 0.22 to 0.03)/−2.71 1.30 (0.97–1.74) 1.01 (0.70–1.45)
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Table 3 Multivariate associations of homocysteine with CRAEs
Results are calculated with linear regression analyses, and are shown as standardized β values (St. β ) (95 % CI)/change in μm.
Model Added variables CRAE [St.β (95 % CI)/change in μm]
1 Homocysteine, age, sex and glucose tolerance status − 0.20 (− 0.33 to − 0.07)/− 3.78
2 As model 1+plasma SAM and 5-MTHF − 0.25 (− 0.39 to − 0.09)/− 4.73
3 As model 1+HbA1c, SBP, DBP, BMI, total cholesterol, microalbuminuria and prior CVD − 0.22 (− 0.35 to − 0.09)/− 4.16
4 As model 2+HbA1c, SBP, DBP, BMI, total cholesterol, microalbuminuria and prior CVD − 0.25 (− 0.41 to − 0.09)/− 4.73
mortality [1,2]. In addition, hyperhomocysteinaemia has
been associated with retinal vascular occlusive disease,
whichwas shown recently in ameta-analysis [15]. In con-
trast with our results, one study including 84 recently dia-
gnosed Type 2 diabetic individuals and 115 non-diabetic
individuals did not find a relationship between plasma
homocysteine levels and AVR [37]. That study, however,
did not use a computer-assisted method to accurately
measure arteriolar and venular diameters, aswe have done
in the present study. Further support for an association
between hyperhomocysteinaemia and microvascular
disease derives from studies of renalmicrovascular disease
[11,13,14], which show an independent association
of homocysteine with the presence and development of
microalbuminuria [13,14]. In addition, Fassbender et al.
[38] demonstrated that homocysteine levels were
increased in 82 subjects with cerebral microangiopathy
compared with subjects without cerebrovascular disease.
Therefore our present study and previous studies suggest
that hyperhomocysteinaemia may not only be a risk
factor for macrovascular disease, but may also be
associated with microvascular disease in the retina and
elsewhere.
Our present results have shown that subjects with
homocysteine levels in the highest tertile had an 8 μm
smaller retinal arteriolar diameter compared with
subjects with homocysteine levels in the lowest tertile.
To put this into perspective, higher blood pressure (a
known determinant of retinal arteriolar narrowing) was,
in our present study, associated with decreases of 0.6
and 1.1 μm in retinal arteriolar diameter per 10 mmHg
higher SBP and DBP respectively, which is comparable
with previous findings [39,40]. Therefore these findings
suggest that homocysteine could be a biologically
relevant risk factor for retinal arteriolar narrowing.
The exact mechanism by which homocysteine
affects the vascular system is not completely understood.
However, homocysteine is thought to exert its toxic
effects on the vascular wall by impairing endothelial
function, increasing oxidative stress, decreasing
availability of NO, inducing a prothrombotic state and
inducing proliferation of smooth muscle cells [2,9]. This
may cause vasoconstriction, intimal thickening, medial
hyperplasia, hyalinization and sclerosis, consequently
leading to a smaller arteriolar lumen.
We did not find any association between homocysteine
and prevalent retinopathy. Previously, Hoogeveen et
al. [16] found a significant relationship between homo-
cysteine and retinopathy in diabetic subjects, but not in
non-diabetic subjects in the Hoorn Study population
in 1989. These discordant findings might be due to
the limited power of the present study (n= 32 with
retinopathy), which might also explain the absence of
an interaction with diabetic status. Moreover, selective
mortality of diabetic individualswith hyperhomocystein-
aemia [41] may have resulted in a ‘healthy survivor effect’
and may have affected our results. On the other hand,
results on the association between homocysteine and
diabetic retinopathy are not consistent [42,43].
Unlike total plasma homocysteine, a lower plasma
SAM/SAH ratio was strongly associated with retinal
sclerotic vessel abnormalities and retinopathy. Previous
studies have shown that a low SAM/SAH ratio was
associated with end-stage renal failure [44], peripheral
arterial occlusive disease [23] and vascular disease (stroke
and myocardial infarction) [45]. Our additional results
that the plasma SAM/SAH ratio was associated, in a
borderline significant manner, with microalbuminuria
support these findings. Indeed, the ratio of SAMand SAH
is crucial in the regulation of multiple enzymatic trans-
methylation reactions [46]. A decrease in this ratio may
result in inhibition of transmethylation reactions, which
affects the biosynthesis of proteins, hormones, phospho-
lipids, neurotransmitters, RNA and DNA [47,48] and,
consequently, might lead to inhibition of vascular endo-
thelial cell growth [49] and impairment of endothelial
function. In addition, increased SAH, which could be
caused by elevated homocysteine concentrations, also
potentially acts as an inhibitor of transmethylation reac-
tions [46]. Taken together, we hypothesize that a de-
crease in transmethylation reactions may be an important
factor in the pathogenesis of retinal microvascular
disease.
In the present study, we used a detailed measurement
of retinal microvessel diameters by a computer-assisted
method on fundus photographs made in mydriasis.
Moreover, we used the revised formulas of Parr and
Hubbard to quantify vessel calibre, by which the vessels
were measured independently of image scale and the
number of measured vessels [31]. A second advantage
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of the present study is its population-based design,
including subjects with and without Type 2 diabetes.
The present study also has limitations though. The
result that homocysteine is associated with retinal
arteriolar narrowing and plasma SAM/SAH ratio is
only associated with sclerotic vessel abnormalities and
retinopathy might be confusing, suggesting different
pathophysiological mechanisms. As the complete patho-
physiological pathway of the association between homo-
cysteine/methionine metabolism and microangiopathy is
still unclear, our results may represent different patho-
physiological pathways; however, we cannot exclude the
possibility that these differences are caused by chance.
Owing to the cross-sectional design of the present
study, we cannot interpret the results as cause-and-effect
relationships. In addition, the study population consisted
of individuals aged 60–85 years with a considerable
prevalence of cardiovascular risk factors, and we do not
knowwhether the results of the present study can be gen-
eralized to a younger or healthier population, or to other
ethnicities.However, anolder population alsohas advant-
ages in the study of homocysteine and its components,
because homocysteine levels increase with age and low
to low-normal concentrations or deficiencies in folate
and vitamin B12 are relatively common in this age group,
which provide wider ranges of concentrations to study in
the elderly.
In conclusion, this is the first population-based study
that shows an independent relationship of total plasma
homocysteine with retinal arteriolar narrowing. In
addition, the plasma SAM/SAH ratio was strongly asso-
ciated with retinal sclerotic vessel abnormalities and ret-
inopathy. This suggests that homocysteine and, possibly,
reduced transmethylation reactions may be involved
in the pathogenesis of retinal microvascular disease.
Further studies are needed to clarify the microvascular
effects of homocysteine-lowering treatment with folate,
which may also increase transmethylation reactions [50],
in order to create new treatment modalities for (retinal)
microvascular disease.
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